NEWS

Notice of Annual General Meeting in Modus Therapeutics Holding AB (Publ) – in Swedish

Modus Therapeutics Announces the Results of its Global, Randomized, Placebo-Controlled Phase 2 Clinical Trial Evaluating Sevuparin for the Management of Acute Vaso-Occlusive Crisis (VOC) in Patients with Sickle Cell Disease (SCD)

Modus Therapeutics strengthens management team with appointment of Mats Blom, MBA as CFO

First Cohort Dosed in U.S. Phase 1 Study of Subcutaneously Administered Sevuparin

Modus Therapeutics strengthens Board with two key appointments

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for treatment of sickle cell disease

Modus Therapeutics completes a SEK 140m financing led by HealthCap

Sevuparin receives Rare Pediatric Disease Designation from FDA for the treatment of children with sickle cell disease

Notice of extraordinary General Meeting in Modus Therapeutics Holding AB (Publ)

Dr. John Öhd appointed Chief Medical Officer at Modus Therapeutics